202 related articles for article (PubMed ID: 32554215)
1. Adjuvant chemotherapy in small node-negative triple-negative breast cancer.
Steenbruggen TG; van Werkhoven E; van Ramshorst MS; Dezentjé VO; Kok M; Linn SC; Siesling S; Sonke GS
Eur J Cancer; 2020 Aug; 135():66-74. PubMed ID: 32554215
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
[TBL] [Abstract][Full Text] [Related]
4. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer.
Carbajal-Ochoa W; Bravo-Solarte DC; Bernal AM; Anampa JD
Breast Cancer Res Treat; 2024 Jan; 203(2):257-269. PubMed ID: 37833449
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
Du ZL; Wang Y; Wang DY; Zhang L; Bian ZM; Deng Y; Xu CS; Lin DC; Xie L; Jia Y; Gao JD; Zhang BL
Breast Cancer Res Treat; 2020 Sep; 183(2):429-438. PubMed ID: 32647940
[TBL] [Abstract][Full Text] [Related]
6. Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis.
Crozier JA; Pezzi TA; Hodge C; Janeva S; Lesnikoski BA; Samiian L; Devereaux A; Hammond W; Audisio RA; Pezzi CM
Lancet Oncol; 2020 Dec; 21(12):1611-1619. PubMed ID: 33271091
[TBL] [Abstract][Full Text] [Related]
7. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Use and Impact of Chemotherapy in Lymph Node-Negative, T1a Triple-Negative Breast Cancer.
Bravo-Solarte DC; Zhang F; Anampa JD
Clin Breast Cancer; 2023 Oct; 23(7):763-773.e6. PubMed ID: 37648557
[TBL] [Abstract][Full Text] [Related]
9. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature.
An X; Lei X; Huang R; Luo R; Li H; Xu F; Yuan Z; Wang S; de Nonneville A; Gonçalves A; Houvenaeghel G; Li J; Xue C; Shi Y
Cancer; 2020 Aug; 126 Suppl 16():3837-3846. PubMed ID: 32710666
[TBL] [Abstract][Full Text] [Related]
11. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
[TBL] [Abstract][Full Text] [Related]
12. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
13. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of adjuvant radiotherapy in triple-negative breast cancer: A historical cohort study.
Bhoo-Pathy N; Verkooijen HM; Wong FY; Pignol JP; Kwong A; Tan EY; Aishah Taib N; Nei WL; Ho GF; Tan B; Chan P; Lee SC; Hartman M; Yip CH; Dent R
Int J Cancer; 2015 Nov; 137(10):2504-12. PubMed ID: 26018878
[TBL] [Abstract][Full Text] [Related]
15. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
Bell R; Brown J; Parmar M; Toi M; Suter T; Steger GG; Pivot X; Mackey J; Jackisch C; Dent R; Hall P; Xu N; Morales L; Provencher L; Hegg R; Vanlemmens L; Kirsch A; Schneeweiss A; Masuda N; Overkamp F; Cameron D
Ann Oncol; 2017 Apr; 28(4):754-760. PubMed ID: 27993816
[TBL] [Abstract][Full Text] [Related]
16. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
Park JH; Jonas SF; Bataillon G; Criscitiello C; Salgado R; Loi S; Viale G; Lee HJ; Dieci MV; Kim SB; Vincent-Salomon A; Curigliano G; André F; Michiels S
Ann Oncol; 2019 Dec; 30(12):1941-1949. PubMed ID: 31566659
[TBL] [Abstract][Full Text] [Related]
18. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
Wu W; Wu M; Peng G; Shi D; Zhang J
Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population.
Lim S; Park SH; Park HK; Hur MH; Oh SJ; Suh YJ
PLoS One; 2015; 10(11):e0140208. PubMed ID: 26562837
[TBL] [Abstract][Full Text] [Related]
20. A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.
Kubo M; Kawai M; Kumamaru H; Miyata H; Tamura K; Yoshida M; Ogo E; Nagahashi M; Asaga S; Kojima Y; Kadoya T; Aogi K; Niikura N; Miyashita M; Iijima K; Hayashi N; Yamamoto Y; Imoto S; Jinno H
Breast Cancer Res Treat; 2019 Dec; 178(3):647-656. PubMed ID: 31451979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
